Fixed dosing of liposomal Amphotericin B in morbidly obese individuals

Author(s):
Wasmann, R.E.; Smit, C.; Dongen, E.P.H. van; Wiezer, R.M.J.; Adler-Moore, J.; Beer, Y.M. de; Burger, D.M.; Knibbe, C.A.J. (0000-0001-9893-4415); Bruggemann, R.J.M.
Published
2019
Publication type
Article / Letter to editor

Abstract

Abstract

In this prospective study, we examined the pharmacokinetics of 1 and 2 mg/kg liposomal amphotericin B in 16 morbidly obese individuals (104–177 kg). Body size had no effect on clearance. We recommend a fixed dose in patients ≥100 kg (ie, 300 or 500 mg rather than the current dose of 3 and 5 mg/kg, respectively).

Clinical Trials Registration NCT02320604.

fungal treatmentfungal infectionobesepopulation pharmacokineticsoptimal dosing
Date issued
2019-10-07
Language
English
Publisher
Oxford University Press
Is part of
Clinical Infectious Diseases (2019), Vol. 70, no. 10, p. 2213-2215
hdl
1887/85270
doi
10.1093/cid/ciz885